Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity
- 31 December 1991
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 45 (4-5) , 203-207
- https://doi.org/10.1016/0753-3322(91)90109-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumoursBritish Journal of Cancer, 1990
- Superiority of perfusion over bolus administration in cancer chemotherapy: Proposition of a compartmental modelMedical Hypotheses, 1989
- Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trialCancer, 1989
- Continuous infusion of high-dose cisplatin in children: Pharmacokinetics of free and total platinumEuropean Journal of Cancer and Clinical Oncology, 1987
- A model for ultrafilterable plasma platinum disposition in patients treated with cisplatinCancer Chemotherapy and Pharmacology, 1987
- Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curveJournal of Pharmacokinetics and Biopharmaceutics, 1986
- Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatinBiochemical Pharmacology, 1984
- CisplatinAnnals of Internal Medicine, 1984
- Reporting results of cancer treatmentCancer, 1981
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977